Daptomycin in paediatrics: Current knowledge and the need for future research

Nicola Principi, Michela Caironi, Francesca Venturini, Luca Pani, Susanna Esposito

Research output: Contribution to journalArticle

Abstract

To overcome the problems stemming from antimicrobial resistance, there have been several attempts to develop new antimicrobials in recent years. Of the highly potent drugs targeting resistant Gram-positive bacteria, daptomycin has a number of attractive characteristics that suggest its possible use in the treatment of serious infections due to these organisms. Although several pharmacokinetic and clinical studies in adults have provided data to determine howthis drug should be prescribed to obtain the maximal clinical efficacy without significant risks of severe adverse events, we have not yet solved all of the problems related to the use of this antibiotic in paediatric patients. In this paper, the resolved and lingering problems of daptomycin treatment in newborns and children are reviewed and discussed. Studies have indicated that daptomycin is a promising therapeutic option for the treatment of paediatric diseases caused by MDR Gram-positive bacilli. However, before daptomycin can be licensed for use in newborns and children, further studies are needed to establish the appropriate dosages for paediatric patients of different ages. The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients. Thus, studies in neonates and younger infants are urgently needed to permit the use of daptomycin in the first months of life, a period in which infections due to MDR Gram-positive pathogens are increasing.

Original languageEnglish
Article numberdku453
Pages (from-to)643-648
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume70
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Daptomycin
Pediatrics
Newborn Infant
Gram-Positive Bacteria
Therapeutics
Drug Delivery Systems
Infection
Bacillus
Pharmacokinetics
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Antibiotic resistance
  • Enterococcus
  • Gram-positive bacteria
  • Staphylococcus aureus
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases
  • Medicine(all)

Cite this

Principi, N., Caironi, M., Venturini, F., Pani, L., & Esposito, S. (2015). Daptomycin in paediatrics: Current knowledge and the need for future research. Journal of Antimicrobial Chemotherapy, 70(3), 643-648. [dku453]. https://doi.org/10.1093/jac/dku453

Daptomycin in paediatrics : Current knowledge and the need for future research. / Principi, Nicola; Caironi, Michela; Venturini, Francesca; Pani, Luca; Esposito, Susanna.

In: Journal of Antimicrobial Chemotherapy, Vol. 70, No. 3, dku453, 01.03.2015, p. 643-648.

Research output: Contribution to journalArticle

Principi, N, Caironi, M, Venturini, F, Pani, L & Esposito, S 2015, 'Daptomycin in paediatrics: Current knowledge and the need for future research', Journal of Antimicrobial Chemotherapy, vol. 70, no. 3, dku453, pp. 643-648. https://doi.org/10.1093/jac/dku453
Principi, Nicola ; Caironi, Michela ; Venturini, Francesca ; Pani, Luca ; Esposito, Susanna. / Daptomycin in paediatrics : Current knowledge and the need for future research. In: Journal of Antimicrobial Chemotherapy. 2015 ; Vol. 70, No. 3. pp. 643-648.
@article{fcbbaef9caf64c60bc720273185a7cfd,
title = "Daptomycin in paediatrics: Current knowledge and the need for future research",
abstract = "To overcome the problems stemming from antimicrobial resistance, there have been several attempts to develop new antimicrobials in recent years. Of the highly potent drugs targeting resistant Gram-positive bacteria, daptomycin has a number of attractive characteristics that suggest its possible use in the treatment of serious infections due to these organisms. Although several pharmacokinetic and clinical studies in adults have provided data to determine howthis drug should be prescribed to obtain the maximal clinical efficacy without significant risks of severe adverse events, we have not yet solved all of the problems related to the use of this antibiotic in paediatric patients. In this paper, the resolved and lingering problems of daptomycin treatment in newborns and children are reviewed and discussed. Studies have indicated that daptomycin is a promising therapeutic option for the treatment of paediatric diseases caused by MDR Gram-positive bacilli. However, before daptomycin can be licensed for use in newborns and children, further studies are needed to establish the appropriate dosages for paediatric patients of different ages. The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients. Thus, studies in neonates and younger infants are urgently needed to permit the use of daptomycin in the first months of life, a period in which infections due to MDR Gram-positive pathogens are increasing.",
keywords = "Antibiotic resistance, Enterococcus, Gram-positive bacteria, Staphylococcus aureus, Streptococcus pneumoniae",
author = "Nicola Principi and Michela Caironi and Francesca Venturini and Luca Pani and Susanna Esposito",
year = "2015",
month = "3",
day = "1",
doi = "10.1093/jac/dku453",
language = "English",
volume = "70",
pages = "643--648",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Daptomycin in paediatrics

T2 - Current knowledge and the need for future research

AU - Principi, Nicola

AU - Caironi, Michela

AU - Venturini, Francesca

AU - Pani, Luca

AU - Esposito, Susanna

PY - 2015/3/1

Y1 - 2015/3/1

N2 - To overcome the problems stemming from antimicrobial resistance, there have been several attempts to develop new antimicrobials in recent years. Of the highly potent drugs targeting resistant Gram-positive bacteria, daptomycin has a number of attractive characteristics that suggest its possible use in the treatment of serious infections due to these organisms. Although several pharmacokinetic and clinical studies in adults have provided data to determine howthis drug should be prescribed to obtain the maximal clinical efficacy without significant risks of severe adverse events, we have not yet solved all of the problems related to the use of this antibiotic in paediatric patients. In this paper, the resolved and lingering problems of daptomycin treatment in newborns and children are reviewed and discussed. Studies have indicated that daptomycin is a promising therapeutic option for the treatment of paediatric diseases caused by MDR Gram-positive bacilli. However, before daptomycin can be licensed for use in newborns and children, further studies are needed to establish the appropriate dosages for paediatric patients of different ages. The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients. Thus, studies in neonates and younger infants are urgently needed to permit the use of daptomycin in the first months of life, a period in which infections due to MDR Gram-positive pathogens are increasing.

AB - To overcome the problems stemming from antimicrobial resistance, there have been several attempts to develop new antimicrobials in recent years. Of the highly potent drugs targeting resistant Gram-positive bacteria, daptomycin has a number of attractive characteristics that suggest its possible use in the treatment of serious infections due to these organisms. Although several pharmacokinetic and clinical studies in adults have provided data to determine howthis drug should be prescribed to obtain the maximal clinical efficacy without significant risks of severe adverse events, we have not yet solved all of the problems related to the use of this antibiotic in paediatric patients. In this paper, the resolved and lingering problems of daptomycin treatment in newborns and children are reviewed and discussed. Studies have indicated that daptomycin is a promising therapeutic option for the treatment of paediatric diseases caused by MDR Gram-positive bacilli. However, before daptomycin can be licensed for use in newborns and children, further studies are needed to establish the appropriate dosages for paediatric patients of different ages. The data collected in adults can only be transferred to children older than 12 years, and the information available is not sufficient to determine the dosage that will assure the highest antimicrobial efficacy with only marginal risks of adverse events in younger patients. Thus, studies in neonates and younger infants are urgently needed to permit the use of daptomycin in the first months of life, a period in which infections due to MDR Gram-positive pathogens are increasing.

KW - Antibiotic resistance

KW - Enterococcus

KW - Gram-positive bacteria

KW - Staphylococcus aureus

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84928174103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928174103&partnerID=8YFLogxK

U2 - 10.1093/jac/dku453

DO - 10.1093/jac/dku453

M3 - Article

C2 - 25406298

AN - SCOPUS:84928174103

VL - 70

SP - 643

EP - 648

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 3

M1 - dku453

ER -